Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | TNKS | O95271 | 6/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260917 | 0.84 | KDM4E (0.49) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL3236883 | 0.84 | PARP1 (0.45) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL13313210 | 0.77 | PARP1 (0.41) | KDM4ERAB9AKMT2ACYP1A2PARP1 | |
| SCHEMBL20352579 | 0.76 | SMN1; SMN2 (0.47) | KDM4EALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL17867403 | 0.75 | CYP1A2 (0.47) | KDM4ERAB9AKMT2ACYP1A2PARP1 | |
| SCHEMBL25067600 | 0.72 | CYP1A2 (0.53) | KDM4EL3MBTL1RAB9AKMT2ACYP1A2 | |
| SCHEMBL3243139 | 0.71 | KDM4E (0.54) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| Xanthurenate SCHEMBL29394132 | 0.71 | KDM4E (0.59) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| Xanthurenate SCHEMBL29911018 | 0.71 | KDM4E (0.59) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| Xanthurenate SCHEMBL379760 | 0.71 | KDM4E (0.59) | KDM4EL3MBTL1KDM4AEGLN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558585-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-09-25 | — | — | EP | disclosed |
| EP-1558585-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-09-25 | — | — | EP | disclosed |
| CN-1720238-B | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD | 2011-08-03 | — | — | CN | disclosed |
| EP-2210892-A2 | Neurologically-active compounds | Prana Biotechnology Limited (AU) | 2010-07-28 | — | — | EP | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-1558585-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2008-07-02 | — | — | EP | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| CN-1720238-A | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD (AU) | 2006-01-11 | — | — | CN | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167000-A1 | Neurologically-active compounds | ACHE, PSEN1, PSEN2 | KDM4E 3333/4885L3MBTL1 2099/4885KDM4A 3484/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | KDM4E 3329/4885L3MBTL1 2272/4885KDM4A 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.